SANA Sana Corp Company Short-Term Debt

Sana Biotechnology, Inc. - graphic logo of issuer SANA

Sana Biotechnology (SANA) business development relies on scientific achievements that are independent of economic cycles or seasonality, ensuring stability provided there is sufficient capital. This historical price chart on GURU.Markets reflects the asset's dynamics, where the indicator stands at 0.02. The company's activities in developing gene therapies are protected by patents, yet require colossal investments and complex regulatory approvals.

SANA sana.com Short-Term Debt (07/04/2022 - 10/30/2026)

Analytical breakdowns and data insights for company Sana Corp (SANA)

- current quotes and average value forecast:
Price Chart Sana Biotechnology, Inc.|SANA - Average Forecast Price
- market capitalization data:
Market Value Sana Biotechnology, Inc.|SANA - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Sana Biotechnology|SANA - Total Stockholders' Equity|Market Capitalization to Book Value Ratio sana.com|SANA - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Sana Biotechnology|SANA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Sana Biotechnology|SANA - Aggregate Debt Obligations|Debts to Book Capitalization Sana Biotechnology, Inc.|SANA - Company Long-Term Liabilities|Company Short-Term Debts Sana Biotechnology|Quick Liquidity sana.com
- earnings and multiples data:
SANA - Company Net Income
General company analysis:Sana Biotechnology, Inc. (SANA)
Flagship merchandise of sana.com

When constructing a long-term portfolio, it is critical to assess capital loss risks through the lens of liquidity. This indicator aggregates all obligations with a maturity of up to one year, determining the business's short-term solvency. For Sana Biotechnology (SANA), which invests in complex R&D for cell therapies, this balance defines its financial stability. By analyzing the current debt obligations chart, an investor can see the issuer's actual operational headroom.

Competitor analysis

LEGN - Company Short-Term Debt|Short-Term Debt Autolus Therapeutics PLC|Allogene Therapeutics Inc (ALLO) - Company Short-Term Debt|RNAC (Selecta Biosciences Inc.) - Company Short-Term Debt|Company Short-Term Debt Cellectis SA|Short-Term Debt cariboubio.com CRBU|Company Short-Term Debts TIL|genenta.com (GNTA) - Short-Term Indebtedness|Century Therapeutics, Inc. - Company Current Liabilities|Jasper Therapeutics Inc (JSPR) - Short-Term Debt|SNTI: Company Current Liabilities|Company Short-Term Loans and Borrowings ADAP (Adaptimmune)|CERO: Company Short-Term Debts|Company Current Liabilities Alaunos Therapeutics, Inc.|ACHL (Achilles Therapeutics PLC) - Company Short-Term Debts|Short-Term Debt CARGO Therapeutics, Inc CRGX|Company Short-Term Debt Poseida Therapeutics (PSTX)|Company Short-Term Debt TSVT (2seventybio.com)|Company Short-Term Debt Gracell Biotechnologies Inc. GRCL